Company news

Neuren Pharmaceuticals Limited news in 2023

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2023, newest first.

View company

Completion of enrolment in Neuren's Angelman P2 trial

December 19, 2023

Investor presentation, 18 December 2023

December 17, 2023

P2 trial shows significant improvements in Phelan-McDermid

December 17, 2023

Neuren completes enrolment in Pitt Hopkins Phase 2 trial

December 4, 2023

DAYBUE net sales US$66.9 million in Q3 2023

November 2, 2023

Q3 2023 quarterly activity and cash flow report

October 19, 2023

S&P DJI Announces September 2023 Quarterly Rebalance

September 1, 2023

Q2 2023 quarterly activity and cash flow report

July 30, 2023

Neuren receives US$100m for expanded DAYBUE agreement

July 27, 2023

Neuren and Acadia expand global partnership for trofinetide

July 13, 2023

Neuren completes enrolment in Phelan-McDermid Phase 2 trial

June 29, 2023

Neuren opens first site in US for Prader-Willi Phase 2 trial

June 28, 2023

Neuren receives US$40m milestone payment

June 7, 2023

Q1 2023 quarterly activity and cash flow report

April 27, 2023

DAYBUE (trofinetide) launched in US - Neuren earns US$40m

April 18, 2023

FDA approves Daybue - the first treatment for Rett syndrome

March 12, 2023

Neuren reports 2022 full-year results

February 23, 2023

Appendix 4E and 2022 full year accounts

February 23, 2023

Q4 2022 quarterly activity and cash flow report

January 30, 2023

Prader-Willi syndrome IND for NNZ-2591 approved by FDA

January 22, 2023

Decks in 2023